Registration Dossier

Toxicological information

Repeated dose toxicity: oral

Currently viewing:

Administrative data

Endpoint:
short-term repeated dose toxicity: oral
Type of information:
experimental study
Adequacy of study:
other information
Reliability:
3 (not reliable)
Rationale for reliability incl. deficiencies:
other: Documentation insufficient for assessment (small number of animals, treatment time rather short, only the max dose given, only high dose results reported Thus no dose-effect relationship can be derived).

Data source

Referenceopen allclose all

Title:
No information
Author:
Giddings M. et al. (1994). Evaluation of risks to health from environmental exposure in Canada. Environm. Carcino.Ecotox. Revs. C12, 517-525
Title:
No information
Author:
Rimmington C and G Ziegler (1963). Experimental porphyria in rats induced by chlorinated benzenes. Biochem. Pharmacol. 12, 1387-1397

Materials and methods

Principles of method if other than guideline:
Method: other: 3 rats, gradually increased dosing, only maximum dose reported, urinary porphyrins, porphobilinogen and delta- aminolaevulic acid were determined in 24-hours samples, liver examined Controls: solvent, Allylisopropylacetamid, Sed
GLP compliance:
no

Test material

Reference
Name:
Unnamed
Type:
Constituent
Details on test material:
IUCLID4 Test substance: other TS: 1,2,3-trichlorobenzene, no data on purity

Test animals

Species:
rat
Strain:
not specified
Sex:
male

Administration / exposure

Route of administration:
oral: gavage
Duration of treatment / exposure:
7 days
Frequency of treatment:
daily
Doses / concentrations
Remarks:
Doses / Concentrations:
up to 785 mg/kg bw (max. dose) dissolved in 1% celofas
Basis:

Control animals:
yes
Details on study design:
Post-exposure period: no

Results and discussion

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

RS-Freetext:
Urinary porphyrins and porphyrin percursers were the first apparent sign  of intoxication:
max dose: 785 mg/kg bw versus solvent control:
36.59 versus 4.3-6.8 µg/day Coproporphyrin, 
0.72 versus 0.1-0.3 µg/day uroporphyrin, 
57.38  versus 2.5-6.5 µg/day porphobilinogen, 
36.26 versus 38.7-51.6 µg/day delta-aminolaevulic acid
clinical signs:
weight loss, extreme weakness, ataxia, clonic contractions, slight tremor
liver examination:
degeneration of individual liver cells without actual necrosis, or small  areas showing focal necrosis in the central midzonal and periportal region

Applicant's summary and conclusion